Unilateral Ventilation on Cardiopulmonary Bypass During Cardiac Surgery
Unilateral Ventilation on Cardiopulmonary Bypass During Cardiac Surgery in Patients at Increased Risk for Severe Postoperative Pulmonary Complications
Visão geral do estudo
Status
Status
Condições
Condições
- Circulação extracorpórea
- Ultrassom pulmonar
- Tomografia por impedância elétrica (TIE)
- Ventilação monopulmonar
- Ventilação Protetora Pulmonar
- Avaliação da Água Pulmonar
- Complacência pulmonar
- Radiografia de tórax para avaliação clínica
- Complicações Pulmonares em Pacientes Cirúrgicos
- Biomarcadores de lesão endotelial vascular
- Índices de oxigenação
- Pacientes Cardíacos de Alto Risco
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Martin Dworschak, MD, MBA
- Número de telefone: 41090 +43-1-40400
- E-mail: martin.dworschak@meduniwien.ac.at
Estude backup de contato
- Nome: Edda M. Tschernko, MD, MBA
- Número de telefone: 41060 +43-1-40400
- E-mail: edda.tschernko@meduniwien.ac.at
Locais de estudo
-
-
State of Vienna
-
Vienna, State of Vienna, Áustria, 1090
- General hospital Vienna
-
Contato:
- Martin Dworschak, MD, MBA
- Número de telefone: 41090 +43-1-40400
- E-mail: martin.dworschak@meduniwien.ac.at
-
Contato:
- Edda M. Tschernko, MD, MBA
- Número de telefone: 41060 +43-1-40400
- E-mail: edda.tschernko@meduniwien.ac.at
-
Investigador principal:
- Martin Dworschak, MD, MBA
-
Subinvestigador:
- Edda M. Tschernko, MD, MBA
-
Subinvestigador:
- Keso Skhirtladze-Dworschak, MD
-
Subinvestigador:
- Florentina Zingher, MD
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Patients at increased risk for postoperative pulmonary complications
- Major elective cardiac surgery
- Prolonged duration of cardiopulmonary bypass
- Patients older than 65 years of age
- Informed consent
Exclusion Criteria:
- Emergency
- Urgent procedures
- Patients with implanted pacemakers
- Patients with internal cardioverter/defibrillators
- Decompensated cardiac disease
- Pulmonary disease
- Recent pneumonia
- Need for temporary perioperative mechanical support
- Patients not willing to participate
- Treatment with inhaled nitric oxide
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Risk group
Lung ventilated during cardiopulmonary bypass using single-lung ventilation via double-lumen tube.
|
This lung will be ventilated during cardiopulmonary bypass using volume-controlled ventilation with a tidal volume of 3 mL/kg ideal body weight, a PEEP of 5 cmH2O, a respiratory rate of 10/min, and a fraction of inspired oxygen of 30%.
The contralateral lung will not be ventilated during cardiopulmonary bypass and will be allowed to collapse.
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Lung aeration score of both lungs.
Prazo: Lung ultrasound investigations will be performed at baseline, i.e., before surgery, on the day of surgery, and on day 1 and 2 after surgery in the intensive care unit.
|
The aeration score of each lung is the sum of the aeration scores determined in each of six lung quadrants in each lung, which can range from 0 (normal ventilation) to 3 (atelectasis/consolidation).
|
Lung ultrasound investigations will be performed at baseline, i.e., before surgery, on the day of surgery, and on day 1 and 2 after surgery in the intensive care unit.
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Radiologic assessment of Kerley B lines as indicators of lung edema.
Prazo: Performed on the day of surgery and on day 1 and 2 after surgery on the intensive care unit.
|
Number of Kerley B lines in both lungs determined by chest x-ray where stage 1 (no Kerley B lines) reflects best outcome, stage 2 (Kerley B lines become visible) indicates interstitial edema, and stage 3 (increased number of Kerley B lines also in non-dependent areas and partially obscured in dependent parts of the lung) are a sign of alveolar edema.
|
Performed on the day of surgery and on day 1 and 2 after surgery on the intensive care unit.
|
|
Presence of pleural effusion in chest x-ray.
Prazo: Performed on the day of surgery and on day 1 and 2 after surgery on the intensive care unit.
|
Severity assessment will be semi-quantitative with 0 = no effusion, 1 = small effusion (with blunting of the basal lung segments and the costophrenic angle), 2 = moderate effusion (fluid extents to the mid-hemithorax creating a "meniscus sign"), and 3 = massive effusion (the whole lung appears opaque with displacement of the heart to the contralateral side if located unilaterally).
|
Performed on the day of surgery and on day 1 and 2 after surgery on the intensive care unit.
|
|
Determination of the Global Inhomogeneity (GI) index in both lungs separately by thoracic Electrical Impedance Tomography (EIT).
Prazo: On the day of surgery and on day 1 and 2 after surgery in the intensive care unit.
|
Global inhomogeneity is calculated as the sum of the absolute differences between the median value of tidal variation and every single pixel value, divided by the sum of all impedance values, to normalize the calculated values.
A GI index closer to 0 represents highly homogeneous (even) ventilation.
Higher values (i.e., > 0.5) indicate that some parts of the lung are over-distended while others are poorly aerated or collapsed (atelectasis).
|
On the day of surgery and on day 1 and 2 after surgery in the intensive care unit.
|
|
Worst oxygenation (Horowitz) index measured per day during routine blood gas checks.
Prazo: Assessed on the day of surgery and on day 1 and 2 after surgery.
|
The Horowitz index (HI) is calculated by diving arterial oxygen partial pressure determined in the blood gas by the fraction of inspired oxygen.
It will be assessed after each blood gas check and the lowest HI during one day will be entered for further statistical analysis.
The degree of impaired lung function will be determined as follows: HI > 300 mmHg (healthy lung function), HI between 201-300 mmHg (mild lung injury), HI between 101-200 mmHg (moderately severely impaired lung function), and HI < 100 mmHg (severe lung injury, ARDS).
|
Assessed on the day of surgery and on day 1 and 2 after surgery.
|
|
Static lung compliance determined in each lung separately.
Prazo: On the day of surgery in the operating room before and after cardiac surgery on cardiopulmonary bypass when the patient is still ventilated via double lumen tube.
|
Static lung compliance of the ventilated and the non-ventilated lung will be determined twice for each patient.
Static compliance in healthy adults ranges between 60 and 100 mL/cm H₂O.
Values below 50 mL/cm H₂O would be considered abnormally low.
|
On the day of surgery in the operating room before and after cardiac surgery on cardiopulmonary bypass when the patient is still ventilated via double lumen tube.
|
|
Amount of released immune modulators.
Prazo: Determined on the day of surgery as well as on day 1, 2, 3, and 4 after surgery.
|
Serum levels for HSP70, MMP-8, MMP-9, TIMP-1, and Lipocalin-2 will be determined in patients' blood samples, with normal values ranging from 0.2-3 ng/mL for HSP70, 0.3-1.2
ng/mL for MMP-8, 14-100 ng/mL for MMP-9, 80-150 ng/mL for TIMP-1, and 20-130 ng/mL for Lipocalin-2, respectively.
|
Determined on the day of surgery as well as on day 1, 2, 3, and 4 after surgery.
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Length of ICU and hospital stay.
Prazo: These variables will be censored at study completion, on average 30 days.
|
The duration from transfer to the intensive care unit until discharge to a step-down unit and the duration of hospitalization of the patient will be determined in days.
|
These variables will be censored at study completion, on average 30 days.
|
|
In-hospital mortality.
Prazo: In-hospital mortality will be censored at study completion, on average 30 days.
|
It will be recorded if the patient has been discharged from the hospital alive.
|
In-hospital mortality will be censored at study completion, on average 30 days.
|
|
Duration on respiratory support via endotracheal tube.
Prazo: The time until extubation will be censored at study completion, on average 30 days.
|
The hours between arrival of the intubated patient on the intensive care unit until extubation will be determined.
|
The time until extubation will be censored at study completion, on average 30 days.
|
|
Postoperative complications.
Prazo: All complications will be censored at study completion, on average 30 days.
|
Any complication that poses a risk for the patient occurring during the hospital stay and having been documented in the patient's file will be retrieved by carefully reviewing the files and recorded.
|
All complications will be censored at study completion, on average 30 days.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Martin Dworschak, MD, MBA, Medical University of Vienna
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
Outros números de identificação do estudo
- EK Nr: 1250/2021
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .